Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 5;26(12):2272-2287.
doi: 10.1093/neuonc/noae149.

Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma

Megan Montoya  1 , Sara A Collins  1 , Pavlina Chuntova  1 , Trishna S Patel  1 , Takahide Nejo  1 , Akane Yamamichi  1 , Noriyuki Kasahara  1   2   3 , Hideho Okada  1   2   4
Affiliations

Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma

Megan Montoya et al. Neuro Oncol. .

Abstract

Background: Glioblastoma (GBM) has a highly immunosuppressive tumor immune microenvironment (TIME), largely mediated by myeloid-derived suppressor cells (MDSCs). Here, we utilized a retroviral replicating vector (RRV) to deliver Interferon Regulatory Factor 8 (IRF8), a master regulator of type 1 conventional dendritic cell (cDC1) development, in a syngeneic murine GBM model. We hypothesized that RRV-mediated delivery of IRF8 could "reprogram" intratumoral MDSCs into antigen-presenting cells and thereby restore T-cell responses.

Methods: Effects of RRV-IRF8 on survival and tumor growth kinetics were examined in the SB28 murine GBM model. The immunophenotype was analyzed by flow cytometry and gene expression assays. We assayed functional immunosuppression and antigen presentation by ex vivo T-cell-myeloid co-culture.

Results: Intratumoral injection of RRV-IRF8 in mice bearing intracerebral SB28 glioma significantly suppressed tumor growth and prolonged survival. RRV-IRF8 treated tumors exhibited significant enrichment of cDC1s and CD8+ T-cells. Additionally, myeloid cells derived from RRV-IRF8 tumors showed decreased expression of the immunosuppressive markers Arg1 and IDO1 and demonstrated reduced suppression of naïve T-cell proliferation in ex vivo co-culture, compared to controls. Furthermore, DCs from RRV-IRF8 tumors showed increased antigen presentation compared to those from control tumors. In vivo treatment with azidothymidine (AZT), a viral replication inhibitor, showed that IRF8 transduction in both tumor and non-tumor cells is necessary for survival benefit, associated with a reprogrammed, cDC1- and CD8 T-cell-enriched TIME.

Conclusions: Our results indicate that reprogramming of glioma-infiltrating myeloid cells by in vivo expression of IRF8 may reduce immunosuppression and enhance antigen presentation, achieving improved tumor control.

Keywords: IRF8; MDSC; RRV-mediated gene therapy; glioblastoma; immunosuppression.

PubMed Disclaimer

Conflict of interest statement

NK is Chief Scientific Officer at 4D Molecular Therapeutics.

Update of

Similar articles

See all similar articles

References

    1. Mohammed S, Dinesan M, Ajayakumar T.. Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: A retrospective study. Rep Pract Oncol Radiother. 2022;27(6):1026–1036. - PMC - PubMed
    1. Schaff LR, Mellinghoff IK.. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023;329(7):574–587. - PMC - PubMed
    1. Chuntova P, Chow F, Watchmaker PB, et al.Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO immuno-oncology think tank. Neuro-Oncol. 2021;23(3):356–375. - PMC - PubMed
    1. Alban TJ, Alvarado AG, Sorensen MD, et al.Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight. 2264;3(21):e12. - PMC - PubMed
    1. Sharma P, Aaroe A, Liang J, Puduvalli VK.. Tumor microenvironment in glioblastoma: Current and emerging concepts. Neurooncol. Adv.. 2023;5(1):vdad009. - PMC - PubMed

MeSH terms

Substances